MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)
Clinical trials for MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD) explained in plain language.
Never miss a new study
Get alerted when new MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD) trials appear
Sign up with your email to follow new studies for MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising drug aims to stop MOGAD attacks in their tracks
Disease control Recruiting nowThis study tests an investigational drug called satralizumab to see if it can prevent relapses in people with MOGAD, a rare autoimmune disease that attacks the brain and spinal cord. About 152 participants aged 12 and older who have had recent attacks will receive either satraliz…
Matched conditions: MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
Super MRI scans aim to unlock secrets of brain resilience
Knowledge-focused Recruiting nowThis study uses powerful MRI scanners to look at the brains of 700 people, including those with conditions like multiple sclerosis, Alzheimer's, and Parkinson's, as well as healthy volunteers. The goal is to understand why some brains stay healthy while others develop disease. Re…
Matched conditions: MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)
Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated May 13, 2026 16:00 UTC